Cypress plots potential sale in renewed Ramius rejection
This article was originally published in Scrip
Executive Summary
Cypress Bioscience is considering selling its assets or the entire company after issuing its firmest rebuttal yet to its activist shareholder Ramius Value and Opportunity Advisers, a subsidiary of investment management business Ramius LLC.